donanemab

From Aaushi
Jump to navigation Jump to search

Indications

Drug interactions

Mechanism of action

Clinical trials

Notes

More general terms

Additional terms

References

  1. 1.0 1.1 1.2 George J Novel Alzheimer's Drug Appears to Slow Decline - Donanemab shows positive results in small phase II study, says drugmaker. MedPage Today January 11, 2021 https://www.medpagetoday.com/neurology/alzheimersdisease/90636
    George J Novel Anti-Amyloid Slows Cognitive Decline in Phase II Alzheimer Trial. Though benefit was limited in 76-week study, specialists see reasons for optimism. MedPage Today March 13, 2021 https://www.medpagetoday.com/neurology/alzheimersdisease/91625
    Brause D Novel Alzheimer's Drug Slows Cognitive Decline in Phase 2 Trial Medscape - Mar 13, 2021. https://www.medscape.com/viewarticle/947410
    Mintun MA, Lo AC, Duggan Evans D Donanemab in Early Alzheimer's Disease. N Engl J Med 2021; 384:1691-1704. May 6, Online: March 13, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33720637 https://www.nejm.org/doi/full/10.1056/NEJMoa2100708
  2. 2.0 2.1 Hung WH Alzheimer's Disease Treatment on the Horizon or False Dawn? Medscape - Jul 14, 2021. https://www.medscape.com/viewarticle/954015
  3. Shcherbinin A, Evans CD, Lu M et al Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes. The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. Published online September 12, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36094645 https://jamanetwork.com/journals/jamaneurology/fullarticle/2795844
  4. Bender E FDA Says No to Accelerated Approval for Alzheimer's Drug Medscape. Jan 20, 2023 https://www.medscape.com/viewarticle/987276
  5. 5.0 5.1 Lily Investors. News Release. May 3, 2023 Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease. https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional
  6. 6.0 6.1 Sims JR, Zimmer JA, Evans CD et al Donanemab in Early Symptomatic Alzheimer Disease. The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. Published online July 17, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37459141 PMCID: PMC10352931 Free PMC article https://jamanetwork.com/journals/jama/fullarticle/2807533